檢索結果 - Daniel Oder

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y

    Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y 由 Daniel Oder, Nurcan Üçeyler, Dan Liu, Kai Hu, Bernhard Petritsch, Claudia Sommer, Georg Ertl, Christoph Wanner, Peter Nordbeck

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year

    Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year 由 Jonas Müntze, Daniel Gensler, Octavian Maniuc, Dan Liu, Tereza Cairns, Daniel Oder, Kai Hu, Kristina Lorenz, Stefan Frantz, Christoph Wanner, Peter Nordbeck

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study

    Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study 由 Maarten Arends, Christoph Wanner, Derralynn Hughes, Atul Mehta, Daniel Oder, Oliver Watkinson, Perry Elliott, Gabor E. Linthorst, Frits A. Wijburg, Marieke Biegstraaten, Carla E. M. Hollak

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors

    Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors 由 Maarten Arends, Marieke Biegstraaten, Derralynn Hughes, Atul Mehta, Perry Elliott, Daniel Oder, Oliver Watkinson, Frédéric M. Vaz, André B. P. Kuilenburg, Christoph Wanner, Carla E. M. Hollak

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease

    Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease 由 Malte Lenders, Daniel Oder, Albina Nowak, Sima Canaan‐Kühl, Laila Arash‐Kaps, Christiane Drechsler, Boris Schmitz, Peter Nordbeck, Julia B. Hennermann, Christoph Kampmann, Stefan Reuter, Stefan‐Martin Brand, Christoph Wanner, E. Brand

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

    Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study 由 Maarten Arends, Marieke Biegstraaten, Christoph Wanner, Sandra Sirrs, Atul Mehta, Perry Elliott, Daniel Oder, Oliver Watkinson, Daniel G. Bichet, Anzalee Khan, Mark Iwanochko, Frédéric M. Vaz, André B. P. Kuilenburg, Michael L. West, Derralynn Hughes, Carla E. M. Hollak

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: